Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708044 · ClinicalTrials.gov registry record · Phase 1
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01708044 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT01708044, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
Interventions
- OTHER Placebo
- DRUG Pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01708044
The ClinicalTrials.gov registry entry for NCT01708044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01708044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01708044 about?
NCT01708044 is a clinical study titled "Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM". To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
What is the current status of trial NCT01708044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01708044?
The interventions under investigation include: Placebo (OTHER), Pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT01708044?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.